利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.032 秒)

    1-(2H)-ISOQUINOLONE DERIVATIVE
    2.
    发明申请
    1-(2H)-ISOQUINOLONE DERIVATIVE 有权
    1-（2H） - 异喹啉酮衍生物

    公开(公告)号：US20090030195A1

    公开(公告)日：2009-01-29

    申请号：US11816910

    申请日：2006-02-22

    申请人： Kazuo Hattori ,  Satoshi Niizuma ,  Miyako Masubuchi ,  Kohei Koyama ,  Osamu Kondoh ,  Toshiyuki Tsukaguchi ,  Takehiro Okada

    发明人： Kazuo Hattori ,  Satoshi Niizuma ,  Miyako Masubuchi ,  Kohei Koyama ,  Osamu Kondoh ,  Toshiyuki Tsukaguchi ,  Takehiro Okada

    IPC分类号： C07D401/10 ,  C07D413/10

    CPC分类号： C07D491/04 ,  C07D401/04 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14

    摘要： The present invention provides a compound having high antitumor activity, which is useful for therapeutic and preventive agents effective for proliferative diseases such as cancer; a production method thereof; an intermediate compound useful for such production; and a pharmaceutical composition comprising such a compound. The present invention provides a compound represented by the formula (1): wherein X represents an aryl group or heteroaryl group which may be substituted, Cy represents a 4- to 7-membered monocyclic heterocyclic ring or a 8- to 10-membered condensed heterocyclic ring which may be substituted, and Z represents O, S, or NRa; or a prodrug thereof; or a pharmaceutically acceptable salt thereof; and a pharmaceutical and a pharmaceutical composition which comprise the compound.

    摘要翻译： 本发明提供具有高抗肿瘤活性的化合物，其可用于对增殖性疾病如癌症有效的治疗和预防剂; 其制造方法; 用于这种生产的中间体化合物; 和包含这种化合物的药物组合物。 本发明提供由式（1）表示的化合物：其中X表示可被取代的芳基或杂芳基，Cy表示4-至7-元单环杂环或8-至10-元稠合杂环 可以被取代的环，Z表示O，S或NRa; 或其前药; 或其药学上可接受的盐; 以及包含该化合物的药物和药物组合物。

    1-(2H)-isoquinolone derivative
    3.
    发明申请
    1-(2H)-isoquinolone derivative 失效
    1-（2H） - 异喹诺酮衍生物

    公开(公告)号：US20070185160A1

    公开(公告)日：2007-08-09

    申请号：US10588611

    申请日：2005-02-07

    申请人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

    发明人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

    IPC分类号： A61K31/47 ,  C07D217/24 ,  C07D401/02

    CPC分类号： C07D217/24

    摘要： The present invention provides: a compound represented by the following formula (I): [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 represents —NR1R2, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; R1 represents a hydrogen atom, or a C1-8 alkyl group that may be substituted; and R2 represents a C1-8 alkyl group that is substituted with one or more substituents, —COOR3, —COR4, —COSR5, —CONR6R7, —NR22R23, or —C═NR24R25; or R1 and R2, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.

    摘要翻译： 本发明提供：由下式（I）表示的化合物：[其中Y 1和Y 4表示氢原子或卤素原子; Y 2和Y 3中的任一个表示-NR 1 R 2 O 2，另一个表示氢原子 或卤素原子; X表示可被取代的芳基或杂芳基; R 1表示可以被取代的氢原子或C 1-8烷基; 和R 2表示被一个或多个取代基取代的C 1-8烷基，-COOR 3，-COR 2， 4，-COSR 5，-CONR 6，R 7，-NR 22 R SUP > 23 或-C-NR 24 R 25; 或R 1和R 2与它们所键合的氮原子一起可以形成含有至少一个氮原子的4至10元杂环（ 其中所述杂环可以被一个或多个选自组C）的取代基取代，其前药或其药学上可接受的盐; 以及包含该化合物的药物，药物组合物等。

    Front liquid crystal display projector
    5.
    发明授权
    Front liquid crystal display projector 失效
    前置液晶显示投影机

    公开(公告)号：US5993008A

    公开(公告)日：1999-11-30

    申请号：US926749

    申请日：1997-09-10

    申请人： Masanari Hashimukai ,  Takehiro Okada ,  Shozo Aono ,  Makoto Hoshino

    发明人： Masanari Hashimukai ,  Takehiro Okada ,  Shozo Aono ,  Makoto Hoshino

    IPC分类号： G03B33/12 ,  G03B21/00 ,  G03B21/16 ,  G03B21/20 ,  G03B21/22 ,  H04N5/74

    CPC分类号： H04N9/3141 ,  G03B21/16 ,  G03B21/20 ,  G03B21/22

    摘要： A front liquid crystal display projector includes a housing having an exhaust port and a projection opening, an optical block, installed in the housing, having a light source, a reflection mirror, a light separator, an image display unit using liquid crystal, an image combining unit, a projection lens, and an exhaust fan installed between the light source and the exhaust port. The reflection mirror changes the direction of the light from the light source, and the projection lens and the light source are disposed parallel to each other. The exhaust port and the projection opening are provided at a first side of the housing. An image formed by the optical block is projected from the first side and from the projection opening, and air in the housing is discharged from the exhaust port and also from the first side. In addition, the exhaust port prevents stray light from the light source, which exits the exhaust port, from overlapping the image projected from the projection opening.

    摘要翻译： 一种前置液晶显示投影仪，包括具有排气口和突出开口的壳体，安装在壳体中的光学块，具有光源，反射镜，光分离器，使用液晶的图像显示单元，图像 组合单元，投影透镜和安装在光源和排气口之间的排风扇。 反射镜改变来自光源的光的方向，并且投影透镜和光源彼此平行地设置。 排气口和突出开口设置在壳体的第一侧。 由光学块形成的图像从第一侧和突出开口突出，并且壳体中的空气从排气口排出并且也从第一侧排出。 此外，排气口防止离开排气口的光源的杂散光与从突出开口突出的图像重叠。

    LCD Projector
    6.
    发明授权
    LCD Projector 失效
    液晶投影机

    公开(公告)号：US5898521A

    公开(公告)日：1999-04-27

    申请号：US745778

    申请日：1996-11-08

    申请人： Takehiro Okada

    发明人： Takehiro Okada

    IPC分类号： G02B5/30 ,  G02B27/28 ,  G02F1/13 ,  G03B21/00 ,  H04N5/74

    CPC分类号： G02B27/283 ,  H04N5/7441

    摘要： Light from a light source is divided into P-and S-polarized beams by means of a polarizing beam splitter and converted into the same polarized wave. Two polarized waves are incident on a liquid crystal panel symmetrically at the same angle on right and left sides. An integrator comprising two lens arrays is disposed before and behind these polarization converting elements, and therefore brightness can be uniformly increased with a simple construction while achieving space saving.

    摘要翻译： 来自光源的光通过偏振分束器被分为P偏振光束和S偏振光束，并转换为相同的偏振波。 两个偏振波在右侧和左侧以相同的角度对称地入射在液晶面板上。 包括两个透镜阵列的积分器设置在这些偏振转换元件之前和之后，因此可以以简单的结构均匀地增加亮度，同时实现节省空间。

    Triazole derivative and pharmaceutical use thereof
    7.
    发明授权
    Triazole derivative and pharmaceutical use thereof 失效
    三唑衍生物及其药物用途

    公开(公告)号：US5750545A

    公开(公告)日：1998-05-12

    申请号：US586787

    申请日：1996-01-23

    申请人： Fumihiko Akahoshi ,  Takehiro Okada ,  Shinji Takeda ,  Youichiro Naito ,  Chikara Fukaya ,  Shigeki Kuwahara ,  Masahiko Kajii ,  Hiroko Nishimura ,  Masanori Sugiura

    发明人： Fumihiko Akahoshi ,  Takehiro Okada ,  Shinji Takeda ,  Youichiro Naito ,  Chikara Fukaya ,  Shigeki Kuwahara ,  Masahiko Kajii ,  Hiroko Nishimura ,  Masanori Sugiura

    IPC分类号： C07D249/14 ,  C07D487/04 ,  A61K31/41 ,  A61K31/53

    CPC分类号： C07D487/04 ,  C07D249/14

    摘要： An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) ##STR1## or the following formula (III) ##STR2## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

    摘要翻译： PCT No.PCT / JP94 / 01215 Sec。 371日期1996年1月23日 102（e）日期1996年1月23日PCT提交1994年7月22日PCT公布。 公开号WO95 / 03286 日期1995年2月2日预防和治疗免疫相关疾病的药剂，特别是免疫抑制剂，预防和治疗过敏性疾病的药物，预防和治疗嗜酸性粒细胞相关疾病的药剂和嗜酸性粒细胞增多抑制剂 （I）或下式（III）的化合物（III），其中每个符号如说明书中所定义，或 其药学上可接受的盐。 新型单环或双环三唑衍生物。 用于预防和治疗免疫相关疾病的药物，特别是免疫抑制剂，用于预防和治疗过敏性疾病的药物，用于预防和治疗嗜酸性粒细胞相关疾病的药物，嗜酸性粒细胞增多抑制剂和新型三唑衍生物 所有这些都具有优良的嗜酸性粒细胞增多抑制作用和淋巴细胞活化抑制作用。 它们是低毒性和持续性的。 它们在治疗嗜酸性粒细胞和淋巴细胞的积累和活化，炎性呼吸道疾病，嗜酸性粒细胞相关疾病如嗜酸性粒细胞增多和免疫相关疾病方面特别有效。

    1-(2H)-isoquinolone derivative
    9.
    发明授权
    1-(2H)-isoquinolone derivative 失效
    1-（2H） - 异喹诺酮衍生物

    公开(公告)号：US08143274B2

    公开(公告)日：2012-03-27

    申请号：US10588611

    申请日：2005-02-07

    申请人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

    发明人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

    IPC分类号： C07D217/24 ,  A61K31/47

    CPC分类号： C07D217/24

    摘要： The present invention provides: a compound represented by the following formula (I): [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 represents —NR1R2, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; R1 represents a hydrogen atom, or a C1-8 alkyl group that may be substituted; and R2 represents a C1-8 alkyl group that is substituted with one or more substituents, —COOR3, —COR4, —COSR5, —CONR6R7, —NR22R23, or —C═NR24R25; or R1 and R2, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.

    摘要翻译： 本发明提供：由下式（I）表示的化合物：[其中Y 1和Y 4表示氢原子或卤素原子; Y2和Y3中的任一个表示-NR1R2，另一个表示氢原子或卤素原子; X表示可被取代的芳基或杂芳基; R1表示氢原子或可被取代的C1-8烷基; 并且R 2表示被一个或多个取代基-COOR 3，-COR 4，-COSR 5，-CONR 6 R 7，-NR 22 R 23或-C≡NR24 R 25取代的C 1-8烷基; 或R 1和R 2与它们所键合的氮原子一起可以形成含有至少一个氮原子的4至10元杂环（其中杂环可以被一个或多个选自C组的取代基取代 ）]，其前药，或其药学上可接受的盐; 以及包含该化合物的药物，药物组合物等。

    1-(2H)-isoquinolone derivative
    10.
    发明授权
    1-(2H)-isoquinolone derivative 有权
    1-（2H） - 异喹诺酮衍生物

    公开(公告)号：US07820693B2

    公开(公告)日：2010-10-26

    申请号：US11816910

    申请日：2006-02-22

    申请人： Kazuo Hattori ,  Satoshi Niizuma ,  Miyako Masubuchi ,  Kohei Koyama ,  Osamu Kondoh ,  Toshiyuki Tsukaguchi ,  Takehiro Okada

    发明人： Kazuo Hattori ,  Satoshi Niizuma ,  Miyako Masubuchi ,  Kohei Koyama ,  Osamu Kondoh ,  Toshiyuki Tsukaguchi ,  Takehiro Okada

    IPC分类号： A61K31/47 ,  C07D401/10

    CPC分类号： C07D491/04 ,  C07D401/04 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14

    摘要： The present invention provides a compound having high antitumor activity, which is useful for therapeutic and preventive agents effective for proliferative diseases such as cancer; a production method thereof; an intermediate compound useful for such production; and a pharmaceutical composition comprising such a compound. The present invention provides a compound represented by the formula (1): wherein X represents an aryl group or heteroaryl group which may be substituted, Cy represents a 4- to 7-membered monocyclic heterocyclic ring or a 8- to 10-membered condensed heterocyclic ring which may be substituted, and Z represents O, S, or NRa; or a prodrug thereof; or a pharmaceutically acceptable salt thereof; and a pharmaceutical and a pharmaceutical composition which comprise the compound.

    摘要翻译： 本发明提供具有高抗肿瘤活性的化合物，其可用于对增殖性疾病如癌症有效的治疗和预防剂; 其制造方法; 用于这种生产的中间体化合物; 和包含这种化合物的药物组合物。 本发明提供由式（1）表示的化合物：其中X表示可被取代的芳基或杂芳基，Cy表示4-至7-元单环杂环或8-至10-元稠合杂环 可以被取代的环，Z表示O，S或NRa; 或其前药; 或其药学上可接受的盐; 以及包含该化合物的药物和药物组合物。